Interpretation of the efficacy, role and clinical scope of Mobosetinib (Anvili)

Mobocertinib (trade name: Exkivity) is an oral small molecule targeted drug that belongs to a new generation of EGFR inhibitors. It can selectively inhibit the activity of EGFR exon 20 insertion mutation, block abnormal receptor signaling pathways, thereby inhibiting tumor cell proliferation and promoting apoptosis. Compared with traditional EGFR inhibitors, mobosetinib has a stronger inhibitory effect on exon 20 mutations, making up for the lack of efficacy of previous drugs in this mutation group.

Clinical studies have shown that mobosetinib shows significant efficacy in patients with advanced non-small cell lung cancer, especially those who have previously received chemotherapy and are positive for EGFR exon 20 insertion mutations. Its main effects include delaying disease progression, improving objective response rate, and improving patients' quality of life. The drug is administered orally, and patients can take it continuously at home, making treatment more convenient and more consistent.

Mobosetinib is mainly used for patients with locally advanced or metastatic non-small cell lung cancer, and test results show the presence of EGFR exon 20 insertion mutation. It is suitable for patients who are resistant to conventional chemotherapy regimens or other EGFR inhibitors, and is also suitable as an oral targeted therapy option for patients who cannot accept or tolerate intravenous chemotherapy. It is not yet widely approved for use in other types of tumors, but its potential for use in tumors with other EGFR exon 20 mutations is being explored in early clinical trials.

When using moboxetinib, you need to pay attention to adverse reactions, including diarrhea, rash, nausea, loss of appetite, and hematological abnormalities. Clinically, blood routine, liver and kidney function, and weight changes should be regularly monitored. The drug may interact with CYP3A4 inducers or inhibitors, so dose adjustments must be made under the guidance of a physician. Overall, mobosetinib provides an important targeted treatment option for non-small cell lung cancer patients with EGFR exon 20 insertion mutations, and brings new hope to patients who have been ineffective or resistant to previous treatments.

Reference link:https://www.drugs.com